Median Technologies (ALMDT) AI Stock Analysis

• Market Cap: €91.99M
• Dividend Yield: N/A
• Average Volume (3M): 353.48K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.26
• Revenue Growth: 3.25%
• EPS Growth: -2.07%
• Country: FR
• Employees: 225
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Devices
• EPS (TTM): -0.69
• Shares Outstanding: 34,356,567
• 10 Day Avg. Volume: 452,356
• 30 Day Avg. Volume: 353,478
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.00
• Price Target Upside: -25.37% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: €2.00 ▼(-25.37% Downside)

The overall stock score is primarily impacted by the company's challenging financial performance, characterized by negative margins and financial instability. Technical analysis provides some short-term positive signals, but the lack of profitability and valuation concerns weigh heavily on the score.

Median Technologies Business Overview & Revenue Model

Company Description

Median Technologies (ALMDT) is a pioneering company in the field of medical imaging and artificial intelligence. Specializing in the development of imaging biomarkers, Median Technologies provides innovative solutions for the healthcare sector, particularly focusing on the oncology domain. The company's core products and services include software solutions that analyze medical imaging data to enhance clinical decision-making and improve patient outcomes, alongside providing comprehensive services for clinical trials and radiology.

How the Company Makes Money

Median Technologies primarily generates revenue through a combination of software licensing, subscription services, and consulting fees related to its imaging analysis solutions. The company collaborates with pharmaceutical firms, hospitals, and research institutions, offering its expertise in imaging biomarkers to support drug development and clinical research. Key revenue streams include contracts for clinical trial services, where Median provides imaging data management and analysis, and software licenses for its proprietary imaging technology. Additionally, strategic partnerships with major pharmaceutical companies enhance its market reach and contribute to its earnings through joint projects and collaborative studies.

Median Technologies Financial Statement Overview

Summary

Median Technologies is experiencing significant financial challenges. The income statement reveals declining profitability with persistent negative margins. The balance sheet shows financial distress with negative equity, and cash flow analysis indicates unsustainable operations, all suggesting a need for strategic financial restructuring.

Income Statement

Median Technologies has faced declining revenue and profitability over recent years. Despite some growth in revenue from 2020 to 2024, the company has consistently reported negative gross and net profit margins. The EBIT and EBITDA margins are also negative, indicating operational challenges. The negative net income and declining revenue growth rate highlight ongoing financial struggles.

Balance Sheet

The company's balance sheet shows significant financial distress, with a negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio is not calculable due to negative equity, but the large amount of debt relative to assets points to high leverage. The equity ratio is negative, further underscoring financial instability.

Cash Flow

Median Technologies reports negative free cash flow, with a slight improvement in operating cash flow over recent years. The operating cash flow to net income ratio is negative, reflecting unsustainable operations. Free cash flow to net income is also negative, pointing to cash flow challenges that affect financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.95M	22.23M	23.67M	20.55M	13.48M
Gross Profit	-21.07M	-2.55M	24.42M	20.43M	13.34M
EBITDA	-19.28M	-19.59M	-17.48M	-16.94M	-11.21M
Net Income	-25.24M	-22.98M	-20.21M	-19.29M	-12.80M
Balance Sheet
Total Assets	24.37M	35.94M	34.75M	49.39M	25.28M
Cash, Cash Equivalents and Short-Term Investments	8.29M	19.63M	21.67M	39.25M	16.40M
Total Debt	29.44M	23.01M	18.15M	17.45M	4.37M
Total Liabilities	58.34M	46.23M	42.01M	44.45M	36.65M
Stockholders Equity	-33.97M	-10.29M	-7.25M	4.94M	-11.36M
Cash Flow
Free Cash Flow	-19.03M	-21.53M	-17.18M	-10.61M	-5.82M
Operating Cash Flow	-17.95M	-20.24M	-15.79M	-10.13M	-5.46M
Investing Cash Flow	-1.17M	-1.25M	-1.39M	-672.00K	-327.00K
Financing Cash Flow	7.67M	19.72M	-277.00K	33.20M	14.56M

Median Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMDT, the sentiment is Positive. The current price of 2.68 is above the 20-day moving average (MA) of 2.07, above the 50-day MA of 1.95, and below the 200-day MA of 2.85, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 65.00 is Neutral, neither overbought nor oversold. The STOCH value of 81.40 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALMDT.

Median Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	€4.18B	12.96	-41.26%	2.54%	14.43%	-26.74%
ALNOV	49 Neutral	$31.43M	―	-57.82%	―	73.54%	-51.39%
ALMDT	44 Neutral	€91.99M	―		―	3.25%	-2.07%